Gordon Fox • February 15, 2022
Updated thinking on HCM genetics
Many cats have HCM.
HCM is a common inherited disease in cats too – especially in certain breeds like this young Maine coon cat.

Quick summary

Since around 1990, HCM has been regarded as a disease caused entirely by single mutation s in genes affecting a protein in the cardiac sarcomeres. There is no doubt that sarcomere mutations play an important role. But in the last several years, there has been a growing realization among researchers that this cannot be the entire explanation for the causes of HCM. This is because a majority of HCM patients do not appear to carry these mutations, and many people who do carry them never develop HCM. The development and inheritance of HCM are more complicated than was previously thought. However, for patients, many of the lessons previously taught about HCM genetics remain true. Current research may open the way to a much-improved understanding of HCM .

What causes HCM?

What causes HCM? Certain gene mutations (especially in the protein myosin in the heart muscle structures called cardiac sarcomeres ) have been known to be important since 1989-1990 (Jarcho et al. 1989; Solomon et al. 1990). Since then, it seemed that nearly all HCM would be explained this way (Ho and Seidman 2006, Burke et al. 2016). That would be great! If we understood the basis of almost all HCM, we might be able to predict which family members of HCM patients are at most risk of developing HCM. It may even become possible to tune therapies to specific mutations.

Reasons to look for broader answers

But in the last several years, most HCM researchers and specialists have revised their understanding of HCM genetics. Sarcomere mutations play a big role in contributing to HCM. But despite identifying more and more of these mutations (there are more than 1000 currently known), they still explain only about a third (Bos et. al 2014; Gruner et al. 2013) or fewer;(Bonaventura et al. 2019 , Hathaway et al. 2021) of the cases of HCM. What makes matters worse, it’s not uncommon for some people with these mutations to go through life free of HCM. 

All of this makes it difficult to continue to believe that HCM is generally a disease caused by single mutations in the sarcomere (or, in the jargon of genetics, an autosomal dominant mutation). Leading researchers today are investigating broader hypotheses about the causes of HCM (Maron et al. 2019, Harper et al. 2021, Watkins 2021).

What are the other possibilities?

If HCM isn’t mainly explained by mutations in single genes, what are the other possibilities? Most variation in physical characteristics (phenotypes) is caused by a combination of

  • Variation in multiple genes;
  • The ways the genes are regulated;
  • The effects of the environment; and
  • The ways genes affect each other’s expression.

All of these are reasons we speak of mutations as “contributing to” HCM or “promoting” HCM.

Genetics can be complicated!

This isn’t what we all learned in school about genetics. But if you think about it, is it surprising to hear that your teacher’s story was a simplified explanation? After all, if the school science class story was all there was to it, why would we still have people who study how genes work? Some traits work in that simple way, but most don’t.

Which lessons about HCM genetics are unchanged? 

A lot of what you have learned about HCM genetics is still the case, including these points:

  • Each copy of each gene you have (you have 2 of each) has a 1 in 2 (50%) chance of being passed to each child.
  • If you have one of the sarcomere mutations known to promote HCM, each of your children has a 50% chance of inheriting that gene mutation. Their chance of inheriting HCM itself is less than 50% since not everyone with one of these mutations develops disease.
  • If you have HCM but no known mutation, your kids still have a chance of inheriting HCM. We don’t know what that chance is, though, because we don’t understand all the causes of HCM. There is some evidence suggesting that people with non-sarcomere HCM don’t pass on the phenotype as easily as those with sarcomere HCM.
  • A “genetic test” doesn’t test whether your HCM is (partly) caused by genes. It tests whether you have one of the known mutations. In other words, a negative genetic test doesn’t mean you can’t pass your HCM on to your kids. The reason for testing isn’t to exclude YOU, it’s to possibly exclude them from further concern – if you have a known mutation and they don’t, then their chances of developing HCM are exceedingly small.
  • You did not get HCM by eating poorly or failing to exercise. There is no evidence at all for that!

Looking ahead

It may be challenging to process the idea that HCM has more complex causes than previously thought. But humans are complex organisms. Even something as seemingly simple as eye color can be complicated (Mackey 2021). Since the sarcomere mutations we know can cause HCM only account for 30% of cases, we have to keep looking to see if we can find out what’s going on in the majority of HCM cases. The fact that researchers have recognized this means that they can move forward in studying the causes of HCM!

There is a lot to be learned about the causes of HCM.

Learn more about genetics on HCM Awareness Day: https://4hcm.org/hcm-awareness-day/

Literature cited

HCMA Blog

On a green background, a line drawing of a head that has complicated arrows pointing outwards
By Gordon Fox April 25, 2025
Part 2 of a series on making decisions in HCM. A key reason is that decision making is so difficult is that most decisions involve more than one risk.
Hypertrophic Obsctructive Cardiomyopathy
By Erica Friedman April 22, 2025
Bristol Myers Squibb announces that Camzyos has been approved for Obstructive Hypertrophic Cardiomyopathy in Japan.
April 15, 2025
It is hard to believe the first quarter of 2025 is in the history books. In the space of hypertrophic cardiomyopathy and thick heart muscle disorders, the distance between the promise and the delivery of a reality freed from burden of disease is closer than it has ever been, not only in the United States but throughout the world. Unfortunately, we are navigating through some challenging health policy times, which will impact a large percentage of those with the diseases we seek to serve. While we navigate these challenging waters together, we remain committed to ensuring safe, accessible, affordable healthcare while ensuring the rights of those with disabilities are maintained. Last month, I attended two large conferences - one held in Stockholm, Sweden the other Chicago, Illinois. The research communities worldwide are holding their breath, waiting to see how we will move forward, even as we continue to develop new therapies, treatments and, even potentially, cures. It has never been more important to keep research moving, as we are so close to so many amazing improvements in our ability to care for those with thick heart muscle disorders, including HCM in all its forms, Amyloidosis, Fabry’s disease, Danon disease, and RASopathies. There was amazing science presented at the American College of Cardiology, where we warmly welcomed new president, Dr. Christopher Kramer, the original director of the hypertrophic cardiomyopathy center at University of Virginia. We look forward to his leadership and wish him well in his challenging tasks ahead. Later this month we will be in Orlando, Florida - please register and join us for this wonderful Bighearted warrior tour in person with our friends at AdventHealth and the incomparable Dr. Marcos Hazday. I even understand that there's some carpooling being organized from the Tampa area. If you're interested, reach out to the office and we will connect you. Maybe, the most impactful thing that will happen in the month of April is that we will conduct our second visit to Capitol Hill. Our lead topic this year is something you have heard us talk about at many prior meetings of the HCMA and podcasts; the generic drug quality issue. We are proud to be partnering with David Light, Co-founder and President of Valisure, and retired Colonel Vic Suarez, to ask House and Senate members to support the inspection of all generic drugs purchased by the Department of Defense and the Veterans Administration and make results of these inspections open for public use. Secondly, we are seeking rational oversight of health insurance companies’ abuse of prior authorizations and step therapy requirements. These issues cost an estimated 1.3 billion dollars a year and provide nothing to keep a patient safer or a physician's office running more efficiently. Common sense tells us to not waste money where there is no return. Additionally, prior authorizations and step therapies can keep patients sicker longer, ultimately costing the healthcare system more money. Our briefing will educate Representatives to act in an informed manner when moving policies that impact us all. You can watch the video of our briefing from Wednesday, April 9th on Vimeo: https://vimeo.com/event/5043266 If you wish to get involved or more informed on any of the issues above, I encourage you to visit the website, 4hcm.org , or reach out to the office and the staff will be happy to assist you. On the day before I head out to Washington DC, I will leave you with this one thought - we have come a really long way in our understanding of HCM over the past 60 years. We have increased the lifespan of those with HCM, through collaborative research and implementation of best practices in an organized fashion throughout this country. We have worked so hard to end suffering for so many, and we are succeeding in our shared goal to outsmart hypertrophic cardiomyopathy and other thick heart muscle disorders. It is important to continue the research into all aspects of these diseases, including the biological, the clinical, and burden of disease measurements. System improvements, positive impact of timely diagnosis and treatment, and the value to society of all of these big hearts being here, will help keep their families whole. So we're off to DC to try to educate others about what it really means to live in our ecosystem. Best wishes, Lisa
More Posts